Sight Sciences Q3 revenue beats; raises 2026 revenue forecast

Overview

• Eyecare technology firm's Q3 revenue rose 25% yr/yr, beating analyst expectations

• Net loss for Q3 narrowed compared to last year

• Company raised full-year 2026 revenue guidance

Outlook

• Sight Sciences raises 2026 revenue guidance to $92 mln-$93 mln from $88 mln-$92 mln

• Company sees 2026 Interventional Glaucoma revenue at $80 mln-$81 mln and Dry Eye revenue at $12 mln

• Sight Sciences maintains 2026 adjusted operating expenses guidance at $92 mln-$94 mln

Result Drivers

• IDE REVENUE SURGE - Significant growth in Interventional Dry Eye revenue drove overall revenue increase

• IG REVENUE GROWTH - Continued growth in Interventional Glaucoma revenue contributed to overall results

• TECHNOLOGY ADOPTION - Co said increasing adoption of its technologies supported revenue growth

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Sight Sciences, Inc. is $9.00, about 4.5% below its November 3 closing price of $9.42

Reuters Recommended Reads

• Nov 3 - RxSight Q3 revenue falls on competitive pressures

• Nov 3 - Switzerland's Oculis Q3 net loss widens as expenses rise

• Nov 3 - Tarsus Pharmaceuticals Q3 product sales jump 64%, beating estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)